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We studied the antibacterial and antifungal activity of Cymbopogon citratus. These properties were studied on hospital 
isolated multidrug resistant strains Staphylococcus aureus, Staphylococcus aureus, Staphylococcus epidermidis, 
Escherichia coli, Klebsiella pneumonia and their respective ATCC control strains. Pathogenic Candida albicans, Candida 
parapsilosis, and Candida tropicalis were also tested. Results of the present investigation provide evidence that the EO of 
Cymbopogon citratus could have a potential application in the treatment and prevention of diseases caused by 
Staphylococcus aureus methicillin-resistant strains and by vancomicin-resistant Staphylococcus epidermidis. Cymbopogon 
citratus EO is also effective against Candida albicans as well as the emerging Candida parapsilosis and Candida 
tropicalis pointing to its usefulness as an antifungal agent. 
Keywords Antioxidant; non-albicans-Candida species; Gram-positive bacteria; Cymbopogon citratus EO; 
multi-drug resistant bacteria. 
1. Introduction 
Plants have been explored comprehensively as potential sources of antioxidants and antimicrobials [1,2]. The essential 
oil (EO) of C. citratus is often applied in pharmaceutical industry to supply flavor and fragrance, and is also used as a 
source of new phytochemical molecules for the development of novel pharmaceutical products. Several previous studies 
on the leaf EO of C. citratus revealed antityrosinase and antioxidant activity in human cells [3], anti-inflammatory 
activity in rats [4], anti-carcinogenic effects in mice [5], anxiolytic-like effect in mice [6], and cholesterol reduction in 
mice [7]. Furthermore, numerous studies have reported the antimicrobial activity of lemongrass oil against a diverse 
range of microorganisms comprising Gram-positive and Gram-negative bacteria, yeast and fungi [8,9,10]. 
Antimicrobial substances other than antibiotics would be remarkably useful as an adjuvant in the treatment of multi-
resistant strains [11]. 
 The rapid adaptation of pathogenic bacteria to antimicrobial drugs in health care facilities, alongside delayed 
pharmaceutical drug development, has established the need of new molecular approaches. Treating inpatients at health 
institutions is becoming progressively defiant as new antibiotic resistant strains of bacteria and yeasts emerge. To 
overtake this problem it becomes an urgent issue to test new alternatives in antibiotherapy: either the production of new 
drugs or of adjuvants that enhance antimicrobial activity. 
 Multi-drug resistant microbial infections caused by Gram-positive bacteria such as Staphylococcus aureus (S. 
aureus) and Staphylococcus epidermidis (S. epidermidis) represent an exponentially increasing problem that affects 
communities worldwide. S. aureus is an opportunistic pathogen able to colonize the upper respiratory tract and skin 
surfaces in mammals [12]. S. aureus is a common pathogen present in community-acquired infections, most particularly 
skin, soft tissue and respiratory infections and after surgical procedures and methicillin resistant S. aureus nosocomial 
infections [13]. By analyzing the literature of S. aureus one can predict that these bacteria will continue to develop not 
only new virulence but also novel patterns of resistance [14]. 
 S. epidermidis is present on the human skin as normal flora. In hospital environment this bacteria has become a 
problematic pathogen, implicated in health care-associated septicemia, including infections related to vascular catheters 
and prosthetic devices. Several studies have demonstrated that certain multidrug-resistant S. epidermidis genotypes 
become established as opportunistic pathogens in the health care setting as a novel ecological niche [15]. 
Gram-negative bacteria may be opportunistic or commonly pathogenic. They cause a wide variety of infections 
including low and high urinary tract infections, pneumonia and skin and soft tissue infections, among others. The 
avaliable data also refers the emergence of increasingly resistant strains of various Gram-negative bacteria [16]. 







 Candida is a normal commensal of the skin, gastrointestinal and genitourinary tracts but it is also responsible for the 
most prevalent opportunistic fungal infection in humans, and this is of particular significance in patients that present 
risk factors such as  immunosuppression while undergoing treatment for cancer [17], organ transplantation [18], 
receiving broad-spectrum antibiotics, suffering from acute renal failure, previous yeast colonization, neutropenia, 
parenteral nutrition, and central venous catheters [19]. Candida albicans (C. albicans) is the most frequent species 
isolated from clinical specimens, but other Candida species are of special concern, since some are highly virulent and 
are associated with treatment failure due to reduced susceptibility to antifungal agents. Many non-albicans-Candida 
(NCA) species, such as, Candida parapsilosis (C. parapsilosis) and Candida tropicalis (C. tropicalis) have recently 
emerged as important pathogens in immune suppressed individuals. This fact is highlighted by recent epidemiology 
studies reporting that NCA species are currently estimated to be responsible for approximately 60% of fungaemia [20].  
 We studied the antibacterial and antifungal activities of C. citratus. The fact that C. citratus EO has antimicrobial 
activity in bacteria and yeast prompted us to study the effect of this oil on multidrug resistant bacteria and yeasts. 
2. Material and Methods 
2.1. Plant source 
The fresh aerial parts of C. citratus were obtained from a local market in Benguela, (latitude 12º 58’ south; longitude 
13º 408’ east), Angola. The voucher specimen was deposited in the Instituto Superior of Saúde de Benguela, ISPB, 
Benguela, and plants were identified by a taxonomist (Dr. Pedro Catarino Pires, ISPB, Benguela). The fresh plant 
sample was submitted to distillation (4 h) using a Clevenger apparatus to obtain the EO for further analysis. The yield in 
EO was of 1.3%. 
2.2. Antibacterial activity 
2.2.1. Microorganisms 
The tested microorganisms used in this study were obtained from the Culture Collections of the Centro de Investigação 
em Tecnologias da Saúde (CITS). The antimicrobial activity of C. citratus EO was evaluated using the following 
laboratory control strains: S. aureus ATCC 25923, S. epidermidis ATCC 12228, E. coli ATCC 25922, Klebsiella. 
pneumonia (K. pneumonia) ATCC 13883, C. albicans ATCC 10231, C. parapsilosis ATCC 2219 and C. tropicalis 
ATCC 750 and the antibiotic resistant strains isolated from Braga hospital: S. aureus 1; S. aureus 2; S. epidermis 1; S. 
epidermis 2; E. coli 830; E. coli 986; K. pneumonia 822,were a kind gift from Dr. Luisa Mesquita. 
2.2.2. Propagation and maintenance of microorganism 
The studied microorganisms were streaked on the nutrient agar slants and were then incubated overnight at (37±1 ºC). 
The cultures were kept under refrigerated conditions and were sub-cultured every fifteen days. 
2.2.3. In vitro testing  
Empty sterilized discs were impregnated with 5µl of oil diluted with DMSO to attain the different concentrations (5%, 
10%, 20%, 40%, 60%, 80% and 100%), and DMSO was used as control. The inoculated plates were incubated at 37ºC 
for 24 to 48 hours. Antibacterial activity was evaluated by measuring the zone of inhibition in mm against the tested 
bacteria after the incubation period. All experiments were done in triplicate and the results are expressed as 
mean±standard deviation of three independent experiments.  
2.2.3.1. In vitro antibacterial activity 
Antibacterial activity was determined by disk diffusion. A positive control was done using the following antibiotics: 
methicillin (5μg/disc); penicillin (10μg/disc); amoxicillin/clavulanic acid (30μg/disc); vancomycin (5μg/disc) in Gram-
positive strains and ciprofloxacin (5μg/disc), nitrofurantoin (300μg/disc), ceftazidime (30μg/disc); gentamicin 
(10μg/disc) in Gram-negative strains and a negative control was performed with DMSO for all tested strains. The 
antibacterial activity of all the tested antibiotics was interpreted according to the CLSI guidelines [21]. 
2.2.3.2. In vitro antifungal activity 
Antifungal activity was also evaluated by disk diffusion method in accordance to CLSI guidelines M44-A2. Candida 
spp. were tested in agar Miller Hinton (DIFCO) supplemented with 2% of glucose and 0.5g/ml of methylene blue. Yeast 
suspension was adjusted to a final concentration between 1 to 5 x10
6 cells/ml and incubated at 35ºC for 48 hours. The 
antifungal fluconazol at concentration of 5µg per disc was the positive control for Candida spp. Results were 
interpreted based on CLSI guidelines [22]. 







2.3. Statistical analysis  
Data are reported as mean±standard deviation of nine measurements. Statistical analysis was performed using the 
statistical package SPSS v 20.0 (SPSS for Windows; SPSS Inc., Chicago, IL). Mean comparison was made through an 
independent sample t-test. Levene's test was utilized to assess the equality of variances. One-way ANOVA was used to 
compare three or more groups, and post-hoc Dunnett’s test was performed for simultaneous paired comparisons. P 
values less than 0.05 (95% confidence level) are reported as statistically significant.  
3. Results and Discussion 
3.1. C. citratus EO chemical composition 
The results of the chromatographic analysis of the C. citratus EO presented in Table 1 reveal that the chemical 
composition of C. citratus EO obtained from plants grown in Angola is similar to that of C. citratus from other 
provenances [23, 24, 25]. Accordingly, the major constituents are α-citral (40.55%), β-citral (28.26%), myrcene 
(10.50%) and geraniol (3.37%). The volatile fraction of C. citratus EO revealed the presence of 10 different compounds 
accounting for 83.86% of total peak area. 
 
Table 1 Angolan C. citratus EO main components as revealed by GC-MS. 










Linalool isobutyrate  22.967 0.11
aRetention index relative to n-alkanes. 
3.2. Antibacterial activity of C. citratus EO  
The antibacterial activity of C. citratus EO is depicted in Figures 1 and 2. Hospital isolated S. aureus 1 and S. aureus 2 
were sensitive to C. citratus oil concentration equal or higher than 60%. S. aureus ATCC 25923 growth was inhibited at 
lower concentrations equal or superior to 20%. S. epidermidis ATCC 12228 and hospital isolated strain presented a 
similar pattern of sensitivity at concentrations equal or higher than 20%. Both hospital isolated strains of S. aureus 
present a similar pattern of resistance to methicillin, penicillin and amoxicillin-clavulamic acid consistent with 
methicillin resistant profile. S. aureus (ATCC 25923) presented the expected sensitivity to tested antibiotics that usually 
present inhibitory effect on Gram-positive bacteria (Table 2).  
 
 a)  
b) 
Fig. 1 Antimicrobial activity of different EO concentrations of C. citratus against ATCC and multidrug resistant Gram-positive 
hospital isolated strains. *Statistically different (95% significance) from negative control DMSO. 
 
 S. epidermidis 1 was resistant to methicillin, penicillin and amoxicillin-clavulamic acid and vancomycin consistent 
also with the methicillin resistant profile. S. epidermidis 2 was sensitive to amoxicillin-clavulamic acid and resistant to 







penicillin, methicillin and vancomycin. By comparison S. epidermidis ATCC 12228 was sensitive to all antibiotics 




Fig. 2 Antibacterial activity of different EO concentrations of C. citratus against ATCC and multidrug Gram-negative resistant 
strains. *Statistically different (95% significance) relatively to negative control DMSO. 
 
Table 2 Antibiotic sensitivity pattern of multi-drug resistant hospital isolated strains and their respective ATCC control strains. 
Gram-positive 
Bacteria 
MET P AMC 
/AUG 
VA C. citratus  
concentration (%) 
*S. aureus S S S - S ≥ 20 
S. aureus 1 R R R - S ≥ 40 
S. aureus 2 R R R - S ≥ 60 
*S. epidermidis S R S S S ≥ 20 
S. epidermidis 1 R R R R S ≥ 20 
S. epidermidis 2 I R S R S ≥ 20 
Sensitivity values: R – Resistant; I – Intermediate; S – Sensitive. (-) not determined; MET-methilcillin; 
P-penicillin; AMC/AUG-amoxicillin/clavulamic acid; VA-vancomycin (from CLSI guidelines). 
 
 Gram-negative E. coli 830, E. coli 986 and K. pneumoniae 822 presented an intermediate resistance pattern with 
growth inhibition at C. citratus EO concentrations equal or superior to 40%. In E. coli 986 and K. pneumonia 822 this 
pattern was observed in concentrations equal or superior to 20%. This higher resistance pattern, comparatively with that 
of Gram-positive bacteria could be due to the constitution of the outer membrane of Gram-negative bacteria that acts as 
a relatively effective permeability barrier [26]. Gram-negative bacteria are inherently resistant to hydrophobic 
antibiotics, as their outer membrane limits the entry of these antibiotics into the cell [27]. In fact we can hypothesize 
that the C. citratus EO is less effective against Gram-negative bacteria because of the out membrane barrier that these 
bacteria present to hydrophobic molecules [16].  
 These results are in accordance to the data of Onawunmi et al. that uses components of the EO C. citratus, namely 
alpha-citral and beta-citral that individually presented antibacterial activity against Gram-negative [28].  
 
 
Fig. 3 Antifungal activity of different C. citratus EO concentrations against Candida spp. * statistically different (95% significance) 
from negative control DMSO. 
 
 







3.3. Antifungal activity of C. citratus EO against C. albicans and NAC species 
C. citratus EO showed effectiveness in inhibiting the growth of all yeast strains, as is shown in Figure 3. Presented data 
show the antifungal activity at different C. citratus EO concentrations against Candida spp. This sensitivity was also 
shown by these yeast to fluconazol. No effect in yeast growth was shown with DMSO. 
 NCA species exhibited sensitivity to all C. citratus concentrations tested. C. albicans was sensitive to C. citratus oil 
inhibition at all tested concentrations. This data is in accordance with other studies [29, 30]. C. parapsilosis has a 
pathogenic role in neonates, transplant recipients and patients receiving parenteral nutrition [31]. Our results show that 
this species is sensitive to all tested C. citratus concentrations. These data demonstrate high antifungal activity over C. 
parapsilosis, which is an innovative role for C. citratus. 
 C. tropicalis causes infection in neutropenic patients as occurs in malignancy [32]. C. tropicalis is the most prevalent 
of the NAC species, the number of infections of this specie is increasing higher as is its resistance to fluconazol [33]. 
Our results show that this species is sensitive to all C. citratus concentrations tested, being the sensitivity to 80% of this 
oil concentration higher in C. tropicalis. These data demonstrate antifungal activity over C. tropicalis, which is also an 
innovative role for C. citratus (Figure 3). 
 Our results prove the activity of C. citratus EO on C. parapsilosis and C. tropicalis and this suggests further studies 
in order to establish the sensitivity of other clinically relevant NCA species. 
 This evidence shows an antifungal role of C. citratus EO, which should be considered in further investigations. The 
aim should be establishing this extract as an antifungal agent with potential use in common Candida infections. Our 
data show a potential clinical role of this EO in topical therapeutics of NCA species. Published studies show that this 
EO is innocuous in mammals [34] and has shown lack of genotoxic or toxic effects in mice [7, 35]. Studies with the 
infusion of C. citratus in human volunteers have shown no toxic nor adverse effects [35]. 
4. Conclusions 
This oil exhibited high antifungal and antibacterial properties. Although the C. citratus EO inhibition was higher in 
Gram-positive bacteria an effect in Gram-negative bacteria was also shown. At the tested concentrations of the EO we 
obtained an extensive Candida spp. inhibition. This effect was particularly pronounced in NCA species. C. citratus EO 
activity over Gram-positive multi-drug-resistant bacterial strains and over C. albicans and NAC species indicates a 
potential role in preventing spreading of hospital infections, namely by its use as an antiseptic for topical and for hand 
cleaning. Further studies are needed to establish the possibility of the systemic administration of this natural medicine.  
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